A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

What Was Tested

This registered phase 1 trial tested Eloralintide.

For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU) lasting between 4 and 8 days.

There will be 13 other visits.

It had five arms (groups): Eloralintide Cohort 1 (experimental), Eloralintide Cohort 2 (experimental), Eloralintide Cohort 3 (experimental), Eloralintide Cohort 4 (experimental) and Placebo (placebo comparator).

Eloralintide administered subcutaneously (SC).

Eloralintide administered SC.

Eloralintide administered SC.

The registry classes the interventions as drug.

Who Took Part

The registry lists 56 planned participants were the target.

It was open to people of any sex aged from 18 years up to 65 years.

Healthy volunteers could join, not only people with the condition.

Examples of who could join: Have overweight or obesity, but are otherwise overtly healthy. Have a body mass index (BMI) within the range of 27.0 to 45.0 kilograms (kg)/square meter (m²), inclusive. Have had a stable body weight, with less than 5 percent (%) change during the 3-month period prior to screening.

How the Study Was Run

The set-up was randomized, parallel-group and double-blind.

The participants were allocated by chance, so the Eloralintide group and the comparison group should start out alike.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Neither the participants nor the staff measuring them knew who was on Eloralintide, so expectations could not easily colour the readings.

Those kept unaware of assignments: participant and investigator.

It started in 2026-07-31 with completion listed for 2026-12.

It ran at 2 sites in United States (1) and Singapore (1).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Acetaminophen Area Under the Concentration Versus Time Curve (AUC) (time frame: Baseline to Day 65). Acetaminophen Maximum Observed Concentration (Cₘₐₓ) (time frame: Baseline to Day 65). Acetaminophen Time to Maximum Observed Drug Concentration (tₘₐₓ) (time frame: Baseline to Day 65).

It also tracked 2 secondary outcomes, for example Eloralintide AUC and Eloralintide Cₘₐₓ.

What This Means in Plain Language

Put simply, this is a phase 1, randomized trial of Eloralintide in 56 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Eloralintide compound page, all human trials.